FATE
FATE THERAPEUTICS INC
NASDAQ · Healthcare · Biotechnology · US
$1.86
+3.91%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.80
From 52W high−40.19%
Volume1.68M
Market cap$222.87M
P/E (TTM)—
P/S (TTM)34.3x
Div yield—
Key dataOct 19, 2026
Open
$1.80
From 52W high
−40.19%
Volume
1.68M
Market cap
$222.87M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.3x
P/E (TTM)
—
RSI (14)
29.3
MomentumView details →
1D Return
+3.91%
YTD Return
+87.77%
SummaryUpdated Jun 1, 2026
Fate Therapeutics, Inc. (NASDAQ:FATE) is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in San Diego, California. The company went public in 2013 and has established itself as a pioneer in developing off-the-shelf cellular immunotherapies derived from induced pluripotent stem cells (iPSCs). Fate Therapeutics focuses on creating programmed cellular treatments for cancer and autoimmune disorders, representing a cutting-edge approach to cell therapy that could potentially transform how these diseases are treated.
Similar companies
Latest newsMore news →
Fate Therapeutics reported a Q2 2026 loss of $0.25 per share, beating the Zacks Consensus Estimate of a $0.28 loss and improving from a $0.29 loss a year earlier.68d agoFate Therapeutics dosed the first lupus nephritis patient in its Phase 2 potentially registrational trial RECLAIM-LN, utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy, with the patient treated as an outpatient with same-day discharge.68d ago